TPST-4003

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameTPST-4003

Drug Alias NameTPST-4003

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocytes stimulantsB-cell maturation protein modulators +[4]

TargetsB-lymphocyte antigen CD19B-cell maturation protein

Therapy Area/IndicationsImmune System DiseasesLupus Erythematosus, Systemic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTempest Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesTempest Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, Systemic

Inactive IndicationsImmune System Diseases

Other Information

ATC CodeN/A